NADPH oxidase 4 mediates upregulation of type 4 phosphodiesterases in human endothelial cells

Saima Muzaffar1, Jamie Y Jeremy, Gianni D Angelini

  • 1Bristol Heart Institute, University of Bristol, Bristol, UK.

Insights

NADPH oxidase (Nox) upregulation increases type 4 phosphodiesterases (PDE4), reducing cyclic AMP (cAMP) and promoting endothelial cell replication and angiogenesis. This Nox4-PDE4 pathway impacts vascular dysfunction.

Area of Science:

  • Endothelial Cell Biology
  • Vascular Biology
  • Biochemistry

Background:

  • Prostacyclin (PGI2) signaling, mediated by cyclic AMP (cAMP), is crucial for endothelial function.
  • Type 4 phosphodiesterases (PDE4) hydrolyze cAMP, reducing PGI2's protective effects.
  • NADPH oxidase (Nox)-derived superoxide is linked to impaired PGI2 bioactivity.

Purpose of the Study:

  • To investigate the relationship between Nox and PDE4 expression in human umbilical vein endothelial cells (HUVECs).
  • To determine the role of Nox4 and Nox5 in regulating PDE4 expression and endothelial cell functions.

Main Methods:

  • HUVECs were treated with U46619, 8-isoprostane F2α, or TNFα, with or without iloprost.
  • Expression of PDE4 isoforms (A, B, C, D) and Nox4/Nox5 was assessed via Western blotting and qPCR.
  • mRNA silencing of Nox4 and Nox5 was employed to study their functional roles.
  • Effects on cell replication and angiogenesis (tubule formation) were evaluated.

Main Results:

  • U46619, 8IP, and TNFα increased Nox4, Nox5, and all PDE4 isoform expression.
  • These stimuli also enhanced cell replication and tubule formation.
  • mRNA silencing of Nox4, but not Nox5, inhibited these increases.
  • Iloprost and rolipram (a PDE4 inhibitor) also reversed the effects.

Conclusions:

  • Upregulation of Nox4 leads to increased expression of PDE4A, B, and D, augmenting cAMP hydrolysis.
  • This mechanism enhances endothelial cell replication and angiogenesis, contributing to vasculopathies.
  • The PGI2-cAMP signaling axis, modulated by Nox4 and PDE4, is central to endothelial dysfunction in vascular diseases.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...